Advertisement

How Johnson & Johnson Beat Expectations in Q1

How Johnson & Johnson Beat Expectations in Q1

Johnson & Johnson (NYSE: JNJ) has been in the news quite a bit recently. The healthcare giant's COVID-19 vaccine is still on pause in the U.S. due to concerns about rare blood clotting issues. A key facility where the vaccine is manufactured has been temporarily shut down while the U.S. Food and Drug Administration (FDA) conducts an inspection.